pharma · Asthma · Idiopathic pulmonary fibrosis (IPF)
Chiesi Farmaceutici S.p.A
Chiesi Farmaceutici S.p.A is a pharma organization headquartered in Parma, IT. Primary therapeutic focus areas include Asthma, Idiopathic pulmonary fibrosis (IPF), Mild to moderate asthma, Pulmonary fibrosis, Chronic obs
Via Paradigna, 131, Parma, Emilia-Romagna 43122, IT HQ
6,080 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Via Paradigna, 131, Parma, Emilia-Romagna 43122, IT
- Employees
- 6,080
- Programs
- 20
- Drugs
- 38
- Patents
- 0
CLI-06657AA1-03
Phase 3 · other · Fabry disease (α-galactosidase A deficiency)
CLI-06657AA1-03 for Fabry disease (α-galactosidase A deficiency) is a Phase 3 program (other) at Chiesi Farmaceutici S.p.A with 1 ClinicalTrials.gov record(s).
Internal code CLI-06657AA1-03
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Chiesi Farmaceutici S.p.A
- Phase
- Phase 3
- Modality
- other
- Indication
- Fabry disease (α-galactosidase A deficiency)
- Status
- active
- Trials
- 1